Physician profile
Patrick C Angelos
NPI 1487857272
$615.24
in general payments reported to CMS, 2019-2025
9 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Facial Plastic Surgery provider received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.41 · 2020: $119 · 2021: $14.67 · 2023: $28.66 · 2024: $136 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $190.62 | 2021-2025 | Scopis Ent |
| Aerin Medical INC. | $170.46 | 2020-2025 | |
| Abbvie INC. | $76.16 | 2024 | |
| Musculoskeletal Transplant Foundation INC. | $59.97 | 2024 | |
| Intersect Ent, INC. | $42.41 | 2019 | |
| Merck Sharp & Dohme LLC | $28.66 | 2023 | |
| Smith+Nephew, INC. | $26.66 | 2025 | Grafix Pl, Stravix |
| Astrazeneca Pharmaceuticals Lp | $20.30 | 2025 | Airsupra |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$187,739.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Angelos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.